Filing Summary
Company: Olema Pharmaceuticals, Inc. Form: 8-K. Report date: April 5, 2021; filed April 6, 2021. The filing reports changes to the company’s board and related director compensation arrangements.
Business Context and Reporting Period
Olema is a Delaware corporation whose common stock trades on The Nasdaq Global Select Market under the symbol OLMA. The filing does not provide operating or financial results for a reporting period.
Board and Governance Changes
- Frank McCormick resigned from the Board effective April 5, 2021. The company stated that the resignation was not due to any disagreement or dispute.
- Dr. McCormick entered into a consulting agreement with Olema to provide advisory services on scientific matters.
- Yi Larson was appointed as a Class III director effective immediately to fill the vacancy. Her term is expected to expire at the 2023 annual meeting of stockholders.
- Ms. Larson was appointed to the Nominating and Corporate Governance Committee and was determined by the Board to be independent under applicable Nasdaq requirements.
- The filing states that there are no arrangements or understandings relating to Ms. Larson’s selection and no reportable related-party transactions under Item 404(a) of Regulation S-K.
Financial Metrics, Liquidity, and Debt
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating and financial metrics.
Director Compensation and Equity Awards
- Ms. Larson received an option to purchase 21,520 shares under the company’s 2020 Equity Incentive Plan. The award vests in 36 equal monthly installments over three years, subject to continued service.
- She also received an option to purchase 3,773 shares, which vests in full on the date of the company’s 2021 annual meeting, subject to continued service.
- Under the non-employee director compensation policy, Ms. Larson is entitled to a $40,000 annual cash retainer, additional committee retainers including $5,000 for Nominating Committee service, and an annual option to purchase 21,520 shares.
- The company entered into its standard indemnification agreement with Ms. Larson.
Material Changes, Outlook, and Risks
The principal material change is the replacement of a departing director and the associated consulting and compensation arrangements. The filing contains no financial guidance or business outlook. Investors should consider the potential dilution and expense implications of the director stock options, although the filing does not quantify their exercise price, fair value, or accounting expense.
Important Facts to Verify
- Confirm the terms, scope, duration, and compensation, if any, under Dr. McCormick’s consulting agreement.
- Review the exercise prices, vesting terms, and fair values of Ms. Larson’s option awards.
- Assess the cumulative dilution from the new director awards and the company’s broader equity incentive plans.
- Confirm Ms. Larson’s continued service through the applicable vesting dates and the 2021 annual meeting.
- Review subsequent filings for additional board changes, compensation updates, or related consulting arrangements.